Thyroid dysfunction in patients with metastatic carcinoma treated with Sunitinib: is thyroid autoimmunity involved?
PANI, FABIANA;BOI, FRANCESCO;MARIOTTI, STEFANO
2015-01-01
Abstract
Sunitinib is a tyrosine kinase inhibitor (TKI) inducing thyroid dysfunction, but the precise mechanism(s) involved remains to be explained, including a role of thyroid autoimmunity. The objective was to evaluate thyroid function, parameters of autoimmunity, and thyroid ultrasound findings in patients with metastatic cancer and normal thyroid function/autoimmunity before the initiation of Sunitinib therapy. This is a prospective, observational cohort study.File | Size | Format | |
---|---|---|---|
Pani et al Thyroid 25_1255_2015.pdf Solo gestori archivio
Description: Articolo principale
Type: versione editoriale
Size 256.37 kB
Format Adobe PDF
|
256.37 kB | Adobe PDF | & nbsp; View / Open Request a copy |
THY-2015-0170-Pani_1P.pdf Solo gestori archivio
Type: versione editoriale
Size 270.98 kB
Format Adobe PDF
|
270.98 kB | Adobe PDF | & nbsp; View / Open Request a copy |
THY-2015-0170.R3.def.pdf open access
Type: versione pre-print
Size 826.66 kB
Format Adobe PDF
|
826.66 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.